ArriVent BioPharma, Inc. 8-K

What Happened
ArriVent BioPharma, Inc. announced the results of its 2026 annual meeting of stockholders held June 18, 2026 via live audio webcast. Of 46,368,442 shares eligible to vote (record date April 21, 2026), a quorum of 33,418,793 shares (72.07%) was present or represented by proxy. Stockholders elected James Healy, M.D., Ph.D., John Hohneker, M.D., and Stuart Lutzker, M.D., Ph.D. as Class II directors for three‑year terms expiring at the 2029 annual meeting. Stockholders also ratified PricewaterhouseCoopers LLP (PwC) as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Meeting date and record date: June 18, 2026 (meeting); April 21, 2026 (record date).
• Quorum: 33,418,793 shares present or represented (72.07% of 46,368,442 eligible shares).
• Director vote totals:
  • James Healy — For: 18,058,285; Withheld: 11,527,650; Broker non‑votes: 3,832,858.
  • John Hohneker — For: 28,043,164; Withheld: 1,542,771; Broker non‑votes: 3,832,858.
  • Stuart Lutzker — For: 29,495,923; Withheld: 90,012; Broker non‑votes: 3,832,858.
• Auditor ratification: PwC ratified — For: 33,411,773; Against: 829; Abstain: 6,191; Broker non‑votes: 0.

Why It Matters
These are routine corporate governance outcomes that confirm the company’s board composition and auditor for 2026. The election results establish who will serve on the board through the 2029 annual meeting and the PwC ratification confirms the independent auditor overseeing the company’s financial reporting for the year. Vote breakdowns (including withheld votes and broker non‑votes) show shareholder participation levels and may be relevant to investors tracking governance support and voting dynamics.